UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000059779
Receipt number R000068341
Scientific Title Research on the long-term consumption of dietary fiber-containing food.
Date of disclosure of the study information 2025/11/25
Last modified on 2025/11/13 17:15:33

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Research on the long-term consumption of dietary fiber-containing food.

Acronym

Research on the long-term consumption of dietary fiber-containing food.

Scientific Title

Research on the long-term consumption of dietary fiber-containing food.

Scientific Title:Acronym

Research on the long-term consumption of dietary fiber-containing food.

Region

Japan


Condition

Condition

Healthy adult

Classification by specialty

Not applicable Adult

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Safety assessment of long-term consumption of dietary fiber-containing food.

Basic objectives2

Safety

Basic objectives -Others


Trial characteristics_1

Others

Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

Safety assessment of long-term consumption of dietary fiber-containing food.

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Continuous intake of test food for 12 weeks

Interventions/Control_2

Continuous intake of placebo for 12 weeks

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

64 years-old >=

Gender

Male and Female

Key inclusion criteria

(1) Male and female aged 20 to 64
(2) Subjects who have a bowel movement frequency of more than 6 times/week or between 3 and 5 times/week
(3) Subjects who fully understand the purpose and content of this study and voluntarily agree to participate in the study

Key exclusion criteria

(1) Subjects who take health foods related to the test food more than 1 day a week
(2) Subjects who habitually take health foods or pharmaceuticals that are expected to have effects that overlap with the product concept
(3) Subjects with a medical condition that may affect the study
(4) Subjects who are diagnosed by a doctor with constipation or irritable bowel syndrome, currently.
(5) Subjects who have had abnormalities in clinical test values or cardiopulmonary function and are judged to be unsuitable for participation in the study
(6) Subjects who are at risk of developing allergies related to the study
(7) Subjects with a disease requiring regular medication, with a disease currently being treated (excluding dry eyes and tooth decay) or with a history of a serious disease that required medication
(8) Subjects whose pre-intake test results are significantly outside the reference range
(9) Subjects who work in shifts, late-night shifts, or have other irregular lifestyles
(10) Subjects who have participated or plan to participate in other studies within one month of the start of the study or during the study
(11) Females who are pregnant, potentially pregnant (only to wish to become pregnant during the study period), or breastfeeding
(12) Subjects who are judged to be unsuitable for participation in the study based on their responses to the lifestyle questionnaire or pre-intake test results
(13) Subjects who are judged as unsuitable for the study by the investigator for other reason

Target sample size

48


Research contact person

Name of lead principal investigator

1st name Masakazu
Middle name
Last name Kobayashi

Organization

Kobayashi Pharmaceutical Co., Ltd.

Division name

R&D Headquarters, Healthcare Product Development Department, Manager

Zip code

567-0057

Address

1-30-3 Toyokawa, Ibaraki-shi, Osaka

TEL

080-3452-9955

Email

masa-kobayashi@kobayashi.co.jp


Public contact

Name of contact person

1st name Akane
Middle name
Last name Morimoto

Organization

EP Mediate Co., Ltd.

Division name

Development Department Trial Planning Section

Zip code

162-0814

Address

Acropolis Tokyo, 6-29 Shin-ogawamachi, Shinjuku, Tokyo

TEL

070-7079-8489

Homepage URL


Email

morimoto.akane003@eps.co.jp


Sponsor or person

Institute

EP Mediate Co., Ltd.

Institute

Department

Personal name



Funding Source

Organization

Kobayashi Pharmaceutical Co., Ltd.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Medical Station Clinic Research Ethics Committee

Address

3-12-8, Takaban, Meguro-ku, Tokyo

Tel

03-6452-2712

Email

epmd_fd-erb@eps.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

メディカルステーションクリニック (Medical station clinic) (東京都)


Other administrative information

Date of disclosure of the study information

2025 Year 11 Month 25 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2025 Year 10 Month 23 Day

Date of IRB

2025 Year 10 Month 23 Day

Anticipated trial start date

2025 Year 11 Month 25 Day

Last follow-up date

2026 Year 05 Month 08 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2025 Year 11 Month 14 Day

Last modified on

2025 Year 11 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000068341